[1] Scholz M,Tselmin S,Fischer S,et al.Hypertriglyceridemia in an outpatient department--Significance as an atherosclerotic risk factor[J].Atheroscler Suppl,2015,18:146-153. [2] Ooi E M,Watts G F,Chan D C,et al.Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-Ⅲ kinetics in the metabolic syndrome[J].Diabetes Care,2008,31(8):1656-1661. [3] Ooi E M,Barrett P H,Chan D C,et al.Apolipoprotein C-Ⅲ:Understanding an emerging cardiovascular risk factor[J].Clin Sci (Lond),2008,114(10):611-624. [4] Klein R L,McHenry M B,Lok K H,et al.Apolipoprotein C-Ⅲ protein concentrations and gene polymorphisms in type Ⅰ diabetes associations with microvascular disease complications in the DCCT/EDIC cohort[J].Journal of Diabetes and Its Complications,2005,19(1):18-25. [5] 周 琴,罗桐秀,谭玉林,等.载脂蛋白CⅢ研究进展[J].心血管病学进展,2009,30(5):798-801. [6] Mendivil C O,Zheng C,Furtado J,et al.Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-Ⅲ and not other small apolipoproteins[J].Arterioscler Thromb Vasc Biol,2010,30(2):239-245. [7] Ito Y,Azrolan N,O'Connell A,et al.Hypertriglyceridemia as a result of human ApoCⅢ gene expression in transgenic mice[J].Science,1990,17(4970):790-793. [8] Ding Y Y,Wang Y H,Zhu H,et al.Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CⅢ[J].Transgenic Res,2011,20(4):867-875. [9] Li H,Han Y,Qi R,et al.Aggravated restenosis and atherogenesis in ApoCⅢ transgenic mice but lack of protection in ApoCⅢ knockouts:The effect of authentic triglyceride-rich lipoproteins with and without ApoCⅢ[J].Cardiovasc Res,2015,107(4):579-589. [10] Kawakami A,Yoshida M.Apolipoprotein CⅢ links dyslipidemia with atherosclerosis[J].J Atheroscler Thromb,2009,16(1):6-11. [11] Pokharel Y,Sun W,Polfus L M,et al.Lipoprotein associated phospholipase A2 activity,apolipoprotein C3 loss-of-function variants and cardiovascular disease:The atherosclerosis risk in communities study[J].Atherosclerosis,2015,241(2):641-648. [12] Hu Z J,Ren L P,Wang C,et al.Associations between apolipoprotein CⅢ concentrations and microalbuminuria in type 2 diabetes[J].Exp Ther Med,2014,8(3):951-956. [13] 杜 玲,刘 刚,陆 健,等.高通量测序技术的发展及其在生命科学中的应用[J].中国畜牧兽医,2014,41(12):109-115. [14] 刘 飞,杨继业,孙志颖,等.牛多个组织microRNA Solexa测序与生物信息学分析[J].中国畜牧兽医,2015,42(6):1409-1416. [15] Suliman M,Yilmaz M,Carrero J,et al.Novel links between the long pentraxin 3,endothelial dysfunction,and albuminuria in early and advanced chronic kidney disease[J].Clin J Am Soc Nephrol,2008,3(4):976-985. [16] Yilmaz M,Axelsson J,Sonmez A,et al.Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria[J].Clin J Am Soc Nephrol,2009,4(3):535-541. [17] Dubin R,Shlipak M,Li Y,et al.Racial differences in the association of pentraxin-3 with kidney dysfunction:The multi-ethnic study of atherosclerosis[J].Nephrol Dial Transplant,2011,26 (6):1903-1908. [18] Zhang J S,Nelson M,Wang L,et al.Identification and chromosomal localization of CTNNAL1,a novel protein homologous to alpha-catenin[J].Genomics,1998,54(1):149-154. [19] Bear M D,Li M,Liu Y,et al.The Lbc Rho guanine nucleotide exchange factor α-catulin axis functions in serotonin-induced vascular smooth muscle cell mitogenesis and RhoA/ROCK activation[J].J Biol Chem,2010,285(43):32919-32926. [20] Kreiseder B,Holper-Schichl Y M,Muellauer B,et al.Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1[J].PLoS One,2015,10(3):1-18. |